Page 32 - OHKF_Biotech_EN

3
•
between the two cities, a “pivot” is required to conduct technology should encompass four main categories of enterprises or
SZ-HK I&T Co-operation Zone as a Pivot: Driving HK-SZ Collaborations Forward
transfer that brings basic research outcomes from Hong Kong into platforms: a cross-border biotech mega research institute,
Shenzhen for mass production. A pivot can also improve subsidiaries of competent national regulators, a one-stop service
governmental, industrial, academic and research linkage between platform dedicated to biotech transfer, as well as star and
the two cities by facilitating the sharing of resources and facilities unicorn enterprises.
like research funding, enterprises, parks and national large-scale
scientific facilities between Shenzhen and Hong Kong Apart from housing these facilities and organisations, the Loop
organisations. As the Loop is at the forefront of HK-SZ co-operation, can play a pivotal role in exploring the best and most innovative
enjoying a more flexible regime structure and significant policy biotech policies in relation to cross-border collaboration. When it
support, it is well-positioned to synthesise the research and comes to the overall development direction, the “two parks”
industrial advantages of the two cities and play the role of the pivot should be treated as “one zone” rather than individually: where
in driving forward collaborative development between Hong Kong the two cities differ in systems and standards, the more flexible
and Shenzhen (see Figure 8). system and the more internationalised standards should be
adhered to in order to support the speedy development of
The Loop should establish itself as a comprehensive and advanced industries; and where they differ in incentive policies
multifaceted industrial system that is attractive to sophisticated, and measures, greater incentives and more supportive
leading biomedical enterprises and star enterprises specialised in measures should be adopted. Harmonising such differences can
various biotech subsectors, and commit itself to nurturing help prevent researchers and enterprises from flowing one way
24
promising local start-ups into unicorns. It should also leverage and congregating into a particular park. Such measures will then
Hong Kong’s vital role in connecting mainland China with other enable the Loop to pursue holistic, collaborative development as
countries and create an international innovation powerhouse in a whole, and serve as a pivot that drives the long-term
biotech by congregating the best enterprises from Hong Kong, development of the two cities. We shall elaborate on this further
Shenzhen and abroad. To realise this vision, we believe the Loop in our policy recommendations in Chapter 5 and Chapter 6.

24 Usually refers to privately held start-ups founded within the last ten years with a valuation of over USD 1 billion.
30